N/A
Completed N=36
Protein Bioavailability of Wolffia Globosa (Mankai); Acute Test Meal Effects
Men With Mild Abdominal Obesity
Source: ClinicalTrials.gov NCT03020225 ↗
Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Apr 2022
Primary outcomePrimary: Amino Acid Profile (Blood Biomarkers) — 31.1; 31.1; 30 mmol/L
Summary
The investigators aim to test the protein bioavailability of new specific developed strain of duckweed [Wolffia globose, Mankai] , an aquatic plant, which might serve as a protein source and contains all the 9 essential and the 6 conditional amino acids. The investigators will randomize 36 participants to consume equivalent protein (30gr) content of 3 whole foods items: 1. White cheese (animal protein source, as a reference); 2. Green peas, intact, cooked (plant protein source); 3. Wolffia globosa (Mankai), intact, cooked (plant protein source). The foods will be consumed in the morning, following 12h fasting. The foods will be provided with 250ml mineral water and the blood follow-up frame will be for 3 hours. Primary outcome: Blood amino acid profile.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Amino Acid Profile (Blood Biomarkers) |
31.1; 31.1; 30 | — |
| SECONDARY Glycemic Profile |
97.5; 96; 96.7 | — |
| SECONDARY Lipid Profile |
45.3; 41.9; 44.4 | — |
| SECONDARY Liver Function |
43.2; 42.3; 46 | — |
| SECONDARY Minerals |
4.5; 4.7; 4.5 | — |
| SECONDARY Vitamins |
371.1; 473; 423 | — |
| SECONDARY Glycemic Profile-Insulin |
97.5; 96; 96.7 | — |
| SECONDARY Triglycerides |
172.2; 198; 207.9 | — |
| SECONDARY Liver Enzymes- ASAT |
0.53; 0.49; 0.51 | — |
| SECONDARY Magnesium |
0.87; 0.95; 0.91 | — |
Eligibility Criteria
Inclusion Criteria
- age >30 years; abdominal adiposity (waist circumference: men > 102 cm, women > 88 cm) or dyslipidemia
Exclusion Criteria
- triglycerides>400 mg/dL; serum creatinine>2 mg/dL;
- disturbed liver function;
- pregnant or lactating women;
- presence of active cancer, is receiving or received chemotherapy in the last three years; participation in another trial;
- participants who are treated with Coumadin (warfarin)
Data sourced from ClinicalTrials.gov (NCT03020225). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.